Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

ic pancreatic adenocarcinoma, survival rates are the lowest of any cancer. In 2013, it is estimated that almost 45,000 new cases of pancreatic cancer will be diagnosed. About one-in-78 people in the U.S. will develop the disease, affecting equal numbers of men and women, almost always after the age of 45. Its tendency to spread prior to diagnosis makes it the fourth deadliest cancer with a less than six percent five-year relative survival rate, with more than 38,000 people succumbing to the disease each year.1-2

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible benefits and attributes of PEGPH20, the anticipated enrollment of patients and possible outcomes for the referenced Phase 2 clinical trial, the possible method of action of PEGPH20 and the anticipated presentation of data from Halozyme's Phase 1b trial and the development of the HA diagnostic tool and the potenti
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 /CNW/ - A new ... on the salaries and demographic profiles of new graduates ... the Door – Building Careers for New Grads in ... Research-Based Pharmaceutical Companies (Rx&D) and features data ... Career Focus wage subsidy program from 2013 to 2015. ...
(Date:3/30/2015)... 30, 2015 Immunocore Limited, ... to treat cancer, viral infections and autoimmune disease, ... John Bell , the Regius Professor of Medicine ... for the Strategic Coordination of Health Research, to ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
(Date:3/29/2015)...  Caris Life Sciences® today announced the presentation ... the company,s panomic, comprehensive tumor profiling service, found ... and difficult to treat gynecological cancers may inform ... improve patient outcomes. These studies were presented today ... Gynecologic Oncology (SGO) 2015 Annual Meeting on Women,s ...
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ received ... in adult men and women with androgenic alopecia (AGA) ... of IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. ... over-promise and under-deliver, FDA Clearance underscores the safety and ... more than 80 million men and women who suffer ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2
... Advice Shared Through Dynamic WikiAnswers Q&A ... ... a show of support for National,Breast Cancer Awareness Month, Answers.com,s question ... ), where breast cancer survivors,friends and family have gathered to ask ...
... Win Needed Medical ... Oct. 22 Television medical dramas such as,ER and House ... country to millions of Americans each week. Now, small hospitals,lacking ... - are being given the opportunity to turn the cameras ...
... 22 Genzyme Corp.,(Nasdaq: GENZ ) today ... granted marketing approval for Renvela(TM) (sevelamer carbonate) for,the ... kidney disease on,dialysis. Renvela is a next-generation version ... the United States. "Since its approval in ...
Cached Biology Technology:Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 2Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 3American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 2American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 4FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 5
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... OXFORD, Conn. , March 10, 2015 /PRNewswire/ ... NXTDW) ("NXT-ID" or the "Company"), a biometric authentication ... reports the company,s Wocket™ smart wallet has been ... 2015" by Rethink Modern. Rethink Modern ... sharing modern and innovative items for your home and lifestyle that ...
(Date:3/2/2015)... , March 2, 2015  Businesses have a ... protection company Tharon Rankins Enterprises has announced the ... an ultra-safe way for businesses to protect their ... transactions. Beconux is a biometric ... Enterprises. Functioning similarly to an ATM machine, the ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... be published this week, a research team is challenging a ... to the formation of cancer, possibly breathing new life into ... "turning on" genes involved in abnormal cell proliferation. "The ... other and with external cues via receptors at their surfaces. ...
... defect that causes myotonic muscular dystrophy has revealed that the ... through its effects on two key proteins. A study published ... the loss of a single protein accounts for most of ... a second protein also seems to play an important role. ...
... providing a valuable service to plants, and they certainly ... honey bee carry pollen from one plant to the ... the pollinators aren,t satisfied with their nectar rewards and ... a scenario arises in a number of plant-pollinator mutualisms ...
Cached Biology News:Researchers correct the record about behavior of important human protein tied to cancer 2Researchers correct the record about behavior of important human protein tied to cancer 3Researchers trace effects of genetic defect in myotonic muscular dystrophy 2Researchers trace effects of genetic defect in myotonic muscular dystrophy 3Researchers trace effects of genetic defect in myotonic muscular dystrophy 4Tobacco plant thwarts caterpillar onslaught by opening flowers in the morning 2
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
EPH electrode, cathode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
... adult normal paraffin tissue array is ... proteins of interest in extensive panels ... Rat brain, heart, kidney, liver, lung, ... arrayed on positively charged glass slide. ...
Biology Products: